lonafarnib has been researched along with Atherogenesis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abutaleb, NO; Atchison, L; Bedapudi, A; Cao, K; Choi, L; Gete, Y; Shores, K; Truskey, GA | 1 |
| Brazier, J; Brown, WT; Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, J | 1 |
| Li, Y; Peng, G; Qin, J; Sun, L; Wang, J; Xie, S; Zhong, D | 1 |
3 other study(ies) available for lonafarnib and Atherogenesis
| Article | Year |
|---|---|
Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome.
Topics: Atherosclerosis; Calcinosis; Endothelial Cells; Everolimus; Humans; Induced Pluripotent Stem Cells; Lamin Type A; Progeria | 2023 |
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
Topics: Adolescent; Adult; Alkyl and Aryl Transferases; Atherosclerosis; Cause of Death; Child; Child, Preschool; Clinical Trials as Topic; Cohort Studies; Dimethylallyltranstransferase; Diphosphonates; Drug Therapy, Combination; Female; Genes, Dominant; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Kaplan-Meier Estimate; Lamin Type A; Male; Multicenter Studies as Topic; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Proportional Hazards Models; Protein Precursors; Protein Prenylation; Pyridines; Treatment Outcome; Young Adult; Zoledronic Acid | 2014 |
Lonafarnib is a potential inhibitor for neovascularization.
Topics: Alkyl and Aryl Transferases; Animals; Apolipoproteins E; Atherosclerosis; Cell Polarity; Cell Proliferation; Cytoskeletal Proteins; Endothelial Cells; Gene Expression Regulation; Humans; Mice; Neovascularization, Pathologic; Piperidines; Pyridines | 2015 |